A shared global concern arising from the novel coronavirus pandemic has done little to bring arch-enemies Iran and the United States closer together. Instead, it appears to have further ratcheted up the already bitter war of words.
Iranian President Hassan Rouhani is now accusing Washington of waging “medical terrorism” against his country by denying it access to much-needed medical supplies. “This will linger as a historical disgrace for the American ruling elites, who continue to mount pressure on the Iranian nation under the current circumstances,” Rouhani told a cabinet meeting in Tehran April 8.
With its economy already creaking under financial strains imposed by the US “maximum pressure” policy, Iran has complained that its battle against the coronavirus has been unequal and much tougher than that of other nations. To catch up with the pace of the outbreak, which has killed nearly 4,000 Iranians, Tehran put in a request with the International Monetary Fund (IMF) for $5 billion in emergency loans. While Iran says the request is still being processed, Al-Monitor’s Bryant Harris has been told by a US State Department spokesperson that the White House opposes the loan for Tehran, which “is seeking cash to fund its adventurism abroad, not to buy medicine for Iranians.” US law requires that Washington oppose financial assistance from international financial institutions to countries listed as state sponsors of terror, including Iran.
In his televised address, Rouhani pressed the IMF on resisting US pressure to stonewall the loan. “Neither Iran nor the world public opinion will tolerate discrimination against our country regarding the emergency loan,” he warned, suggesting that as a member state of the international body, Iran is entitled to such loans, the last one of which it received 50 years ago. Rouhani also criticized the United States for “violating” World Health Organization regulations on aiding other states in pandemic preparedness and response planning.
AL-MONITOR All-Access gives you unlimited access to all our journalism, the full Daily Briefing, exclusive interviews, premium newsletters, and live events — for less than $2/week.